Transgene SA (0OCQ.L)
| Previous close | 2.4000 |
| Open | 2.4000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4000 - 2.4000 |
| 52-week range | 2.4000 - 2.4000 |
| Volume | 868 |
| Avg. volume | N/A |
| Market cap | 189.616M |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
STRASBOURG, France & LUND, Sweden, October 01, 2021--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that they will present additional preclinical data on their novel
- Business Wire
Availability of Transgene’s Half-Year Financial Report as of June 30, 2021
STRASBOURG, France, September 22, 2021--Regulatory News: TRANSGENE (Paris:TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2021.
- Business Wire
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
STRASBOURG, France, September 22, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for the six-month period ended June 30, 2021, and provides an update on the progress of its portfolio of clinical-stage drug candidates.
